Neue Optik mit Metamaterialien

Metamaterialien haben besondere optische Eigenschaften: Zum Beispiel brechen sie Licht in eine andere Richtung als alle natuerlichen Materialien, sie haben also einen negativen Brechungsindex. Mit dem EU-Projekt NIM_NIL wollen Wissenschaftler des ISAS solche Metamaterialien fuer sichtbares Licht herstellen.

Trying to understand the interaction of nanoparticles with blood

Emerging nanotechnology applications in the fields of medicine and biology often involve the use of nanoparticles for probing biological processes and structures or for constructing sophisticated nanoscale drug delivery mechanisms. Nanoparticles are already being used with dramatic success in biomedical applications. However, relatively little is known about the potential biological risks from these nanoparticle applications inside the body. The identity of nanoparticles in a biological medium, in terms of their interaction with that medium, is largely determined by the proteins that dress the particles. Since many of the toxic and therapeutic uses of nanoparticles involve the introduction of nanoparticles into the bloodstream of humans and other animals, it is particularly important to know how nanoparticles interact with blood proteins. New research performed in the Polymers Division at the National Institute of Standards and Technology (NIST) directly addresses this issue and explores the effects of nanoparticle size (5nm to 100nm) and a whole range of important blood proteins.

Nanosystems capture and destroy circulating tumor cells

Just as fly paper captures insects, a pair of nanotechnology-enabled devices are able to grab cancer cells in the blood that have broken off from a tumor. These cells, known as circulating tumor cells, or CTCs, can provide critical information for examining and diagnosing cancer metastasis, determining patient prognosis, and monitoring the effectiveness of therapies.

Start-up at California NanoSystems Institute begins clinical trials for wireless body-monitoring system

MediSens Wireless, a startup company in UCLA's on-campus technology incubator at the California NanoSystems Institute, has obtained approval under federal Food and Drug Administration guidelines to begin clinical trials on its novel wireless body-monitoring system, which assesses muscle and neuromotor functions in the upper extremities.